Nova Minerals (Nadaq: NVA) gained critical momentum following a site visit from U.S. Senator Lisa Murkowski to its Estelle Project in Alaska, one of only two U.S. assets independently identified with near-term antimony production potential. The Senator’s support reinforces Estelle’s importance in America’s push for critical minerals independence, aligning with recent federal executive orders aimed at bolstering domestic supply chains for defense and economic resilience. With growing stibnite stockpiles and bipartisan backing, Nova is positioning itself as a future linchpin in U.S. strategic resource supply.

Jupiter Neurosciences (Nasdaq: JUNS) has gone live with its dedicated Nugevia™ website, opening pre-orders for its flagship longevity supplements: GLO, PWR, and MND. Built on Jupiter’s patented JOTROL™ platform, clinically shown to boost resveratrol bioavailability ninefold, the supplements are now available for purchase via subscription or one-time order, with shipping set for Fall 2025. This marks a key commercialization milestone in Jupiter’s strategy to generate consumer revenue alongside its CNS drug development pipeline.

Minovia Therapeutics has been awarded a $350,000 grant from Countdown for a Cure to support the development of novel blood-based mitochondrial biomarkers, designed to identify patients for its proprietary Mitochondrial Augmentation Technology (MAT). The funding will enable collection and analysis of nearly 170 blood samples from both healthy individuals and mitochondrial disease patients to generate individualized “MitoScores.” This milestone further strengthens Minovia’s clinical platform as it prepares for a proposed merger with Launch One Acquisition Corp. (Nasdaq: LPAA), expected to close by year-end.

Atossa Therapeutics (Nasdaq: ATOS) CEO Dr. Steven Quay will discuss the company’s clinical progress and strategic vision at the 27th Annual H.C. Wainwright Global Investment Conference on September 8, 2025. The fireside chat will spotlight (Z)-endoxifen, Atossa’s potent SERM candidate showing promise in both breast cancer treatment and prevention. With multiple clinical trials underway and recent encouraging regulatory feedback, the company is positioning for potential acceleration toward key milestones. A preview video and webcast replay will be available via Atossa’s investor site.